Investigational drug · Phase 3
Rocbrutinib
Also called: LP-168, NWP-775
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
9
Any phase or sponsor naming "Rocbrutinib"
First trial start
2023
Feb 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rocbrutinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Mantle Cell Lymphoma (MCL)
- Mantle Cell Lymphoma
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Follicular Lymphoma ( FL)
- Waldenström Macroglobulinemia (WM)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- CLL / SLL
- CLL (Chronic Lymphocytic Leukemia)
- CLL, Refractory
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Multiple sclerosis · Hematology and blood cancers · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Rocbrutinib" as an intervention, largest first.
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaPivotal-lookingRecruiting
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT07377578 · 394 participants (planned) · Start Feb 5, 2026 · Primary completion May 30, 2031
Drug: Rocbrutinib; Ibrutinib and 3 more · For: Mantle Cell Lymphoma
Sites: Beijing, China; Nanning, China
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLPivotal-lookingRecruiting
Newave Pharmaceutical IncIndustry
NCT07342478 · 306 participants (planned) · Start Apr 23, 2026 · Primary completion Oct 30, 2029
Drug: Rocbrutinib; Pirtobrutinib · For: CLL / SLL; CLL (Chronic Lymphocytic Leukemia); CLL, Refractory and 5 more
Sites: Skokie, Illinois; Bethesda, Maryland; Las Vegas, Nevada · 10 sites in all
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaPivotal-lookingRecruiting
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT07189065 · 150 participants (planned) · Start Nov 27, 2025 · Primary completion Dec 31, 2027
Drug: Rocbrutinib; Bendamustine and 2 more · For: Diffuse Large B-Cell Lymphoma (DLBCL)
Sites: Hefei, China; Beijing, China; Chongqing, China · 41 sites in all
- Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaActive, not recruiting
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT06251180 · 112 participants (planned) · Start Apr 10, 2024 · Primary completion Jun 30, 2027
Drug: Rocbrutinib; Rituximab and 4 more · For: B-cell Non-Hodgkin Lymphoma
Sites: Guangzhou, China
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruiting
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT07609862 · 92 participants (planned) · Start Jul 14, 2026 · Primary completion Jun 30, 2029
Drug: Lacutoclax+Rocbrutinib · For: Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma ( FL) and 2 more
Sites: Tianjin, China
- A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell LymphomaActive, not recruiting
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT05716087 · 62 participants (planned) · Start Feb 21, 2023 · Primary completion Dec 5, 2024
Drug: Rocbrutinib · For: Mantle Cell Lymphoma (MCL)
Sites: Hefei, China; Beijing, China; Chongqing, China · 43 sites in all
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT07570017 · 42 participants (planned) · Start Jun 25, 2026 · Primary completion Dec 31, 2027
Drug: Rocbrutinib; R-GemOx · For: DLBCL
Sites: Guangzhou, China; Shanghai, China
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT07776743 · 30 participants (planned) · Start Aug 2026 · Primary completion Jun 2028
Drug: Rocbrutinib; Dimethyl Fumarate · For: Relapsing-remitting Multiple Sclerosis (RRMS)
Sites: Beijing, China
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT07374224 · 28 participants (planned) · Start Mar 5, 2026 · Primary completion Jun 30, 2026
Drug: Rocbrutinib tablets; Itraconazole capsules and 1 more · For: Clinical Pharmacology
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Rocbrutinib: First Approval.
Fung S · Drugs 2026
- Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study.
Lin N, Cai Q, Zhou K, et al. · Adv Ther 2026
- Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib.
Wang L, Yang D, Shao R, et al. · Clin Transl Sci 2026
- Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting.
Sharma P, Jiang H, Liu D · J Hematol Oncol 2026
- New BTK Inhibitors May Combat Resistance in CLL.
· Cancer Discov 2026
Also in development for Diffuse Large B-Cell Lymphoma (DLBCL)
- BirelentinibDZD8586Phase 37 trials
Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)
- OdronextamabREGN1979, OrdsponoPhase 37 trials
Regeneron · Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed/Refractory Follicular Lymphoma
- AbexinostatPCI-24781Phase 35 trials
Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma
- CyclophosphamidPhase 33 trials
Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer
- CRC01Phase 22 trials
Curocell Inc. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
- LacutoclaxPhase 22 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)
- TRS005Phase 22 trials
Zhejiang Teruisi Pharmaceutical Inc. · CD20-positive Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL)
- REGN9220Phase 21 trial
Regeneron · Diffuse Large B-Cell Lymphoma (DLBCL)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.